Frontlight ResearchEarly access
CompletedPhase 3
A Study of Olezarsen Administered Subcutaneously to Participants With Severe Hypertriglyceridemia
Key facts
- Who runs it
- Ionis Pharmaceuticals, Inc.
- Where
- Atlanta, Baltimore, Birmingham, Bossier City, Boston, Carmel, Charleston, Columbus, DeLand, Eatonton, Flint, Fort Worth, Gainesville, Greenacres City, Houston, Jackson, Jacksonville, Kansas City, Kenosha, Kerrville, Lampasas, Lenoir, Lexington, Little River, Los Angeles, Louisville, Maitland, Marion, McAllen, McKinney, Mesquite, Miami, Mineola, Monroe, Morehead City, Newnan, North Miami Beach, Odessa, Orchard Park, Orem, Orlando, Peoria, Philadelphia, Rapid City, Rochester Hills, Roy, Salisbury, San Antonio, Southaven, Sunrise, Tampa, Tulsa, Webster, and West Palm Beach, United StatesSee the 62 sitesAlso in 22 other countries, 142 sites
- Trial code
- Status
- Completed
- Phase
- Phase 3
- People taking part
- 446 people enrolled
- Started
- 31 Aug 2022
- Ended
- 12 Sept 2025
- Type of study
- Interventional, 2 groupsOne group gets a placebo (a dummy treatment), for comparison.
- Treatments tested
- Olezarsen
- Placebo
- Record updated
- 22 October 2025
Who can take part
- Age
- 18 years and older
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 7 criteriaShow less
Who can take part
- Fasting TG ≥ 500 mg/dL (5.65 mmol/L) at Screening and Qualification
- Participants must be on lipid-lowering therapy that should adhere to standard of care (SOC) per local guidelines. Lipid-lowering medications should be optimized and stabilized for at least 4 weeks prior to screening to minimize changes in these medications during the study
- Participants must be willing to comply with diet and lifestyle recommendations as able
Who cannot take part
- Hemoglobin A1c (HbA1c) ≥ 9.5% at Screening
- Total bilirubin > 1.5 ULN unless due to Gilbert's syndrome
- Estimated GFR < 30 mL/min/1.73 m\^2
- Alanine aminotransferase or aspartate aminotransferase > 3.0 × upper limit of normal
Where in United States
Also in 22 other countries, 142 sites
- Emory UniversityAtlanta, United States
- Maryland Cardiovascular SpecialistsBaltimore, United States
- University of Maryland School of MedicineBaltimore, United States
- Alabama Clinical Therapeutics, LLC AlabasterBirmingham, United States
- Central Research Associates, IncBirmingham, United States
- Grace Research LLCBossier City, United States
- Massachusetts General HospitalBoston, United States
- St. Vincent Medical GroupCarmel, United States
- Medical University of South Carolina (MUSC)Charleston, United States
- The Ohio State University (OSU)Columbus, United States
- DeLand, FloridaHospital not named in the registry
- Accel Clinical ResearchEatonton, United States
- Onyx Clinical ResearchFlint, United States
- Texas Health Family CareFort Worth, United States
- Northeast Georgia Medical CenterGainesville, United States
- Finlay Medical ResearchGreenacres City, United States
- Clinical Trial NetworkHouston, United States
- Juno ResearchHouston, United States
- Pioneer Research Solutions, Inc.Houston, United States
- Vilo Research GroupHouston, United States
- The Jackson ClinicJackson, United States
- University of Florida - JacksonvilleJacksonville, United States
- University of Kansas Medical Center (KUMC)Kansas City, United States
- Clinical Investigation Specialists, Inc.Kenosha, United States
- Sante Clinical Research LLCKerrville, United States
- FMC ScienceLampasas, United States
- Clinical Trials Of America LLCLenoir, United States
- The Research Group of Lexington LLCLexington, United States
- Main Street Physicians Care WaterwayLittle River, United States
- NRC Research InstituteLos Angeles, United States
- Louisville Metabolic and Atherosclerosis Research Center (L-MARC)Louisville, United States
- University of LouisvilleLouisville, United States
- Meridien ResearchMaitland, United States
- SV Research LLCMarion, United States
- DCT- McAllen Primary Care, LLCMcAllen, United States
- Texas Institute of CardiologyMcKinney, United States
- SMS Clinical Research, LLCMesquite, United States
- Southern Endocrinology AssociatesMesquite, United States
- Columbus Clinical ServicesMiami, United States
- NYU Langone Hospital - Long IslandMineola, United States
- Clinical Trials of America LA LLCMonroe, United States
- Diabetes and Endocrinology Consultants, P.C.Morehead City, United States
- Randomize NowNewnan, United States
- Harmony Clinical Research IncNorth Miami Beach, United States
- Permian Research FoundationOdessa, United States
- Orchard Park Family PracticeOrchard Park, United States
- Aspen Clinical ResearchOrem, United States
- Combined Research Orlando Phase I-IVOrlando, United States
- Onyx Clinical ResearchPeoria, United States
- University of PennsylvaniaPhiladelphia, United States
- Monument Health Clinical ResearchRapid City, United States
- Onyx Clinical ResearchRochester Hills, United States
- Ogden Clinic GrandviewRoy, United States
- OnSite Clinical Solutions, LLCSalisbury, United States
- Diabetes & Glandular Disease Clinic, P.A.San Antonio, United States
- Stern CardiovascularSouthaven, United States
- 3Sync ResearchSunrise, United States
- JSV Clinical Research Study IncTampa, United States
- R & B Medical Center LLCTampa, United States
- Oklahoma Heart InstituteTulsa, United States
- Tranquil ResearchWebster, United States
- Metabolic Research InstituteWest Palm Beach, United States
About the trial
What the trial wants to find out
The purpose of this study is to evaluate the efficacy of olezarsen as compared to placebo on the percent change in fasting triglycerides (TG) from baseline.
The 2 groups in the trial
- OlezarsenTreatment being tested
Olezarsen will be administered once every 4 weeks by subcutaneous (SC) injection from Week 1 through Week 49.
- PlaceboPlacebo, for comparison
Olezarsen-matching placebo will be administered once every 4 weeks by subcutaneous (SC) injection from Week 1 through Week 49.
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study of Olezarsen (ISIS 678354) Administered Subcutaneously to Patients With Severe Hypertriglyceridemia
- Publications
- Olezarsen for Managing Severe Hypertriglyceridemia and Pancreatitis Risk.The New England journal of medicine, 2026
- Design and rationale of the CORE-TIMI 72a and CORE2-TIMI 72b trials of olezarsen in patients with severe hypertriglyceridemia.American heart journal, 2025
- Record updated
- 22 October 2025